SNSW(SH:688117) Sou Hu Cai Jing·2025-08-31 03:58Core Viewpoint - The company has shown significant growth in revenue and net profit for the first half of 2025, driven by increased sales of specific raw materials and successful project implementations [2][5]. Group 1: Financial Performance - For the first half of 2025, the company achieved operating revenue of 337.57 million yuan, a year-on-year increase of 69.69% [2] - The net profit attributable to shareholders reached 88.96 million yuan, up 308.29% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 89.48 million yuan, reflecting a 367.92% increase compared to the previous year [2] - Raw material drug revenue was 188.89 million yuan, showing a substantial growth of 232.38%, primarily due to increased exports of Semaglutide and Teriparatide [2] Group 2: Operational Developments - The company has established and expanded its overseas sales team, enhancing its ability to promote international product sales [2] - The company is accelerating the international registration and application of raw materials, optimizing its product layout in key markets such as the US, EU, South Korea, and Russia [2] - New production capacity projects, including a 395 kg peptide raw material production line, have been successfully launched, ensuring order fulfillment [4] Group 3: Product Development and Innovation - The company has developed several innovative beauty peptide raw materials, focusing on anti-wrinkle, whitening, and soothing effects [5] - Collaborations with research institutions have been established to enhance product development, with multiple core beauty peptide raw materials successfully passing international HLL certification [5][6]